Zelluna ASA (FRA:7UM0) Issuance of Debt: €0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7UM0 Zelluna ASA FRA:7UM0
30 GF Score
Price €1.84
! 2 Warning Signs
View Full Analysis

What is Zelluna ASA Issuance of Debt?

Zelluna ASA FRA:7UM0 +1.64% 30 Issuance of Debt is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:7UM0 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Zelluna ASA's Issuance of Debt for the three months ended in Jun. 2026 was €0.00 Mil.

Zelluna ASA's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00 Mil.

Zelluna ASA Issuance of Debt Related Terms

Zelluna ASA Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Zelluna ASA's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelluna ASA Issuance of Debt Chart

Zelluna ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zelluna ASA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7UM0
30GF Score
Zelluna ASA FRA:7UM0
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelluna ASA Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of €0.00 Mil mean?
Zelluna ASA (FRA:7UM0) has a Issuance of Debt of €0.00 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Zelluna ASA and its competitors.
Is Zelluna ASA's Issuance of Debt too high?
Zelluna ASA's current Issuance of Debt is €0.00 Mil. Overall, Zelluna ASA has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's Issuance of Debt compare to VRTX and REGN?
Zelluna ASA's Issuance of Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Zelluna ASA and its competitors. Zelluna ASA's current Issuance of Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (FRA:7UM0) has a current Issuance of Debt of €0.00 Mil. The current Issuance of Debt is €0.00 Mil. Zelluna ASA's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Zelluna ASA (FRA:7UM0), the current Issuance of Debt is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelluna ASA Business Description

Other Exchanges ZLNA:Norway
Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379
Zelluna ASA is a clinical-stage biotechnology company developing cell therapies for solid tumors. It specializes in T cell receptor (TCR)-guided natural killer (NK) cell therapies, known as TCR-NK, which use healthy donor-derived NK cells genetically engineered to express a tumor-specific TCR, enabling the cells to recognize and attack cancer cells. Its lead program, ZI-MA4-1, targets MAGE-A4 in solid tumors with high unmet medical need. Additional programs include ZI-KL1-1 and ZI-PR-1. The company is headquartered in Norway and operates in the oncology and immuno-oncology space, pursuing an allogeneic, off-the-shelf cell therapy approach. Its revenue model centers on research and development of therapeutic candidates, with potential future income from licensing, partnerships, and commercialization of its cell therapy products.
30GF Score

Get the complete analysis for FRA:7UM0

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84
Price